Seattle, WA | July 21, 2015
FOR IMMEDIATE RELEASE: SEATTLE, July 21, 2015: Tanya Parish, Ph.D., Vice President of Drug Discovery, for IDRI (Infectious Disease Research Institute) has been appointed to two prestigious positions: Editor-in-Chief of the scientific journal Microbiology and member of the National Institute of Health’s (NIH) Center for Scientific Review Drug Discovery and Mechanisms of Antimicrobial Resistance Study Section.
Microbiology is a monthly, peer-reviewed journal published by the Society for General Microbiology containing high-quality research papers and topical review articles. Parish was previously a Senior Editor for Microbiology before assuming the role of Editor-in-Chief on July 1, 2015. Professor Charles Dorman, Chair of the Society’s Publishing Committee said, “It is particularly gratifying for the Society to have been able to recruit a scientist of such high caliber and editorial experience to this important position and I wish Dr. Parish every success in her new role.”
Members of NIH Study Sections review grant applications submitted to the NIH, make recommendations on these applications to the appropriate NIH national advisory council or board and survey the status of research in their fields of science. “Members are selected on the basis of their demonstrated competence and achievement in their scientific discipline as evidenced by the quality of research accomplishments, publications in scientific journals, and other significant scientific activities, achievements and honors,” said Richard Nakamura, Ph.D., Director, Center for Scientific Review. “Service on a study section also requires mature judgment and objectivity as well as the ability to work effectively in a group, qualities we believe Dr. Parish will bring to this important task.”
Parish said, “It is an honor to be asked to serve the community in these positions, and I am happy to take on such roles to further the scientific cause. I look forward to working with both the Editorial Board and staff of Microbiology, and the Study Section members and NIH staff over the next few years.”
As a non-profit global health organization, IDRI (Infectious Disease Research Institute) takes a comprehensive approach to combat infectious diseases, combining the high-quality science of a research organization with the product development capabilities of a biotech company to create new diagnostics, drugs and vaccines. IDRI combines passion for improving human health with the understanding that it is not just what our scientists know about disease, but what we do to change its course that will have the greatest impact. Founded in 1993, IDRI has 125 employees headquartered in Seattle with nearly 100 partners/collaborators around the world. For more information, visit www.idri.org.
IDRI: Lee Schoentrup | 206.858.6064 | email@example.com